Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Protein Forest was a biotechnology company specializing in the development of high-resolution protein fractionation tools for proteomics research. The company's flagship technology, the digital Proteome Chip (dPC), employed parallel isoelectric focusing to separate proteins with high precision, significantly enhancing the capabilities of mass spectrometry. These tools were designed to improve biomarker discovery, drug target identification, and the overall efficiency of protein analysis workflows. By providing reproducible and sensitive separation, Protein Forest addressed critical bottlenecks in complex sample preparation. The company's assets were acquired by Pressure BioSciences in 2011 to integrate with their pressure cycling technology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Protein Forest.